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Colorectal cancer is known to arise from multiple tumorigenic pathways; however, the underlying mechanisms remain not
completely understood. Metabolomics is becoming an increasingly popular tool in assessing biological processes. Previous
metabolomics research focusing on colorectal cancer is limited by sample size and did not replicate findings in independent
study populations to verify robustness of reported findings. Here, we performed a ultrahigh performance liquid chromatography-
quadrupole time-of-flight mass spectrometry (UHPLC-QTOF-MS) screening on EDTA plasma from 268 colorectal cancer patients
and 353 controls using independent discovery and replication sets from two European cohorts (ColoCare Study: n = 180
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patients/n = 153 controls; the Colorectal Cancer Study of Austria (CORSA) n = 88 patients/n = 200 controls), aiming to identify
circulating plasma metabolites associated with colorectal cancer and to improve knowledge regarding colorectal cancer etiology.
Multiple logistic regression models were used to test the association between disease state and metabolic features. Statistically
significant associated features in the discovery set were taken forward and tested in the replication set to assure robustness of
our findings. All models were adjusted for sex, age, BMI and smoking status and corrected for multiple testing using False
Discovery Rate. Demographic and clinical data were abstracted from questionnaires and medical records.
What’s new?
Colorectal cancer exhibits certain characteristic changes in metabolic pathways. To expand upon previous findings, these
authors performed a discovery-replication study using two large independent study populations from different countries,
Germany and Austria. They tested metabolic profiles of cancer patients and controls, identifying 691 statistically significant
features in the discovery cohort. Testing the second cohort narrowed it to 97. These corresponded to 28 metabolites, of which
15 could be identified. It will be useful to go forward with prospective analysis on these 15 metabolites, to determine whether
they have predictive or prognostic value.
Background
Colorectal cancer is a major public health concern worldwide, with
1.4 million new cases and an estimated 700,000 deaths annually.1
Colorectal cancer is characterized by a distinct metabolic pheno-
type and changes in key metabolic pathways such as glycolysis or
the tricarboxylic acid (TCA) cycle.2,3 Yet, underlying mechanisms
involved in colorectal carcinogenesis are still unclear4.
Metabolomics is a powerful approach to unravel metabolic
changes associated with disease and is gaining momentum in
the field of cancer epidemiology.5–7 Compared to other
“-omics” techniques, metabolomics is more closely related to a
measured clinical phenotype and is increasingly applied as the
method of choice to screen for potential metabolites associated
with disease status.8,9 Moreover, metabolomics can help to
understand the underlying etiology of cancer development.10
Differences in metabolic profiles have been reported
between colorectal cancer patients and colorectal cancer-free
individuals using nuclear magnetic resonance techniques,11
gas chromatography,12–15 and liquid chromatography-mass
spectrometry methods.16
Various amino acids, such as aspartic acid, have been shown
to be more abundant in cases in different, relatively small, stud-
ies, including a study by Nishiumi and colleagues comparing
serum metabolite levels of 60 colorectal cancer patients and
60 healthy volunteers using gas-chromatography time-of-flight
(TOF) mass spectrometry.13 Similarly, a study by Denkert et al.
examined metabolic profiles in colon tissue and normal mucosa
samples of 27 colorectal cancer patients and 18 colorectal
cancer-free individuals.15 In addition to amino acids, serum
taurine was shown to be more abundant among colorectal can-
cer patients compared to colorectal cancer-free individuals.
Another study among 101 newly diagnosed colorectal cancer
patients reported a clear difference between serum glutamine,
fatty acids, and the urea and TCA cycle metabolites compared
to 102 colorectal cancer-free controls.17
The majority of these previous studies have been limited by
sample size and did not perform replication of their findings in
independent study populations. As metabolomics studies often
identified a wide range of metabolites due to the variety of ana-
lytical platforms, clinical protocols, and sample handling proce-
dures used, leveraging an independent population for
replication using the same platform and similar protocols is
essential to ensure robustness of findings. To date, only few
studies have used a discovery-replication design to reproduce
results in independent study populations.16,18,19 Two of these
studies investigated metabolic differences between colorectal
cancer patients and apparently healthy individuals;16,18 a third
study evaluated metabolomic differences between matched
tumor and healthy colon tissue samples from colorectal cancer
patients.19 In addition, a very recent study investigating meta-
bolic profiles in adenomas, colorectal cancer cases and controls
conducted analysis in two datasets utilizing different metabolo-
mic approaches, but with both sample sets deriving from the
same hospital and cohort.20
To complement current research, we utilized a powerful
combination of untargeted metabolomics analysis, able to
reveal (novel) metabolites, a rigorous discovery-replication
design, leveraging samples deriving from two independent
study populations, as well as relatively large sample sizes to
obtain sufficient statistical power. The overall purpose of our
study was to discover, and replicate plasma metabolites associ-
ated with colorectal cancer to improve knowledge regarding
potential disease etiology.
Methods
Study populations
We utilized data from two cohort studies embedded in the
MetaboCCC Consortium, a consortium of four independent
European cohorts to investigate metabolic profiles across the
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continuum of colorectal carcinogenesis: (1) the Heidelberg site
of the international ColoCare Study (ClinicalTrials.gov Identi-
fier: NCT02328677) and (2) the Colorectal Cancer Study of
Austria (CORSA). The CORSA and ColoCare studies were
selected given the availability of samples from colorectal can-
cer patients as well as controls. EDTA plasma samples from
621 participants were analyzed, consisting of 268 patients with
newly diagnosed colorectal cancer and 353 controls. We
applied independent discovery (ColoCare Study: n = 180
patients/n = 153 controls) and replication (CORSA Study:
n = 88 patients/n = 200 controls) sets using an identical
metabolomics platform (Supporting Information Fig. S1).
The ColoCare Study, in Heidelberg initiated in 2010, is an
ongoing, international, multicenter prospective study includ-
ing women and men newly diagnosed with primary colorectal
cancer. Patients are recruited at the University Hospital of
Heidelberg and the National Center for Tumor Diseases in
Heidelberg, Germany. Participants provided consent prior to
tumor resection if they met the following inclusion criteria:
newly diagnosed colorectal cancer (both colon (ICD-10 C18)
and rectal or recto-sigmoidal cancer (ICD-10 C19/C20)), any
stage of the disease, 18+ years at the time of diagnosis, and
German-speaking. EDTA blood samples from colorectal
cancer patients were collected prior to surgery. Control partic-
ipants were enrolled in the PRAEVENT Study, a population-
based study subjected to similar protocols and procedures,
conducted at the National Center for Tumor Diseases in Hei-
delberg, Germany. All participants consented to take part in
our study and EDTA blood samples were collected during a
visit at the National Center for Tumor Diseases at recruitment
(usually the same day after the consent dialog and after sign-
ing the informed consent form).
In the ongoing CORSA Study participants are recruited in
cooperation with the province-wide screening project “Bur-
genland Prevention Trial of Colorectal Disease with Immuno-
logical Testing” (B-PREDICT), since 2003. All inhabitants of
the Austrian province Burgenland aged between 40 and
80 years are invited annually to participate in fecal occult
blood testing. Positive fecal occult blood tested individuals are
subsequently offered a complete colonoscopy, and EDTA
blood samples are collected prior to examination. Additional
colorectal cancer patients are recruited at the General Hospital
of Vienna (Department of Surgery), and at three additional
hospitals in Vienna. All colorectal cancer patients included in
the CORSA Study are individuals with histologically con-
firmed, sporadic colorectal cancer. CORSA controls are indi-
viduals who received a complete colonoscopy within the
B-PREDICT screening but exhibited no pathological findings
of disease.
All colorectal cancer samples selected for inclusion into the
presented study were collected prior to any clinical treatment,
including surgery or neo-adjuvant therapy, and did not have a
prior history of cancer. Controls included in the study can be
considered as “cancer-free”; having no prior history of cancer.
Patients and controls were 95% of Caucasian origin, recruited
within the last 15 years and selected to be matching according
to their recruitment time point. Clinical data, including tumor
location, staging, and treatment history were abstracted from
medical records. Demographic characteristics (e.g. age, weight,
height and smoking status) were assessed by study-specific
questionnaires. All clinical and demographic data were har-
monized across all cohorts.
Sample collection and analysis
In both cohorts, nonfasted EDTA blood samples were collected
and processed within 4 h, according to identical processing
protocols, and stored at −80 C. Samples at each respective
study site were shipped on dry ice to the International Agency
for Research on Cancer (IARC) in Lyon, France for analysis.
Samples were analyzed with a ultrahigh performance liquid
chromatography- quadrupole time-of-flight mass spectrometry
(UHPLC-QTOF-MS) system (Agilent Technologies) consisting
of a 1,290 Binary LC system, a Jet Stream electrospray ioniza-
tion (ESI) source, and a 6,550 QTOF mass spectrometer. Sam-
ples from each study center were analyzed in cohort-specific
batches, which consisted of five and six 96-well plates for
CORSA and ColoCare, respectively.
A detailed overview of the sample preparation and a com-
plete description of sample analysis by UHPLC-QTOF-MS,
pre-processing of metabolomics data can be found in Support-
ing Information File S1. A summary of the data processing
workflow is shown in Supporting Information Figure S1.
Data analysis
Features with missing values in >50% of either colorectal can-
cer patient or control samples in both populations were
excluded from analysis. The remaining maximum 50% of
missing values were not imputed according to the recommen-
dations of Di Guida et al. 21. Blank adjustment was applied
for the ColoCare and CORSA samples separately; features that
had a minimum relative mean intensity below the relative
mean intensity of blank samples were removed. “Features”
were defined as chromatographic peaks formed by specific
ions, while “compounds” or “metabolites” referred to a con-
firmed molecule that can consist of one or more features
(adducts, clusters and fragments).
Feature intensities were log transformed using the natural
logarithm prior to statistical analysis, to prevent heteroscedas-
ticity.21,22 Demographic and clinical characteristics are pre-
sented as medians with the interquartile range (IQR), or as
numbers with corresponding percentages. Body mass index
(BMI) was calculated as weight (kg) divided by the square of
height (m2). BMI status was categorized based on the recom-
mendations from the World Health Organization (WHO):
underweight (<18.5 kg/m2), normal weight (18.5–24.9 kg/m2),
overweight (25.0–29.9 kg/m2) and obese (≥30.0 kg/m2). Smok-
ing status was categorized as current, former, and never.
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Discovery stage. The discovery analysis was conducted in
ColoCare samples. Log standardized odds ratios (OR.std) and
95% confidence intervals (CIs) were calculated using multiple
logistic regression models with disease state as dependent vari-
able to test the association with feature intensities. The OR.std
represents the change in colorectal cancer occurrence when
there is a one standard deviation (SD) change in metabolite
intensity, allowing comparison of effect sizes between different
features. Since odds ratios were standardized, the SD of the
controls were used to calculate the OR.std. Sex, age, BMI
(continuous), and smoking status were included as covariates
in the final model. Features that showed significant differences
between colorectal cancer patients and controls after correc-
tion for multiple testing, using False Discovery Rate (FDR)
correction, in the discovery stage were carried forward to the
replication stage. A priori, an FDR p-value <0.05 was consid-
ered statistically significant.
Replication stage. The replication stage was conducted in
CORSA Study samples. Significant features (FDR p < 0.05)
from the discovery stage were analyzed in the replication stage
using the same modeling approach as in the discovery stage.
Features were tested if they point in the same direction as the
corresponding effects in the discovery stage (one-sided test-
ing). Analyses were checked for any influence by analytical
batch, but no marked effect could be identified in both stages.
Features with significant test results were selected for identifi-
cation using authentic chemical standards at IARC. A detailed
overview of metabolite identification is explained in Support-
ing Information Table S1. When more than one mass spec-
trometry feature corresponded with a metabolite, the feature
with the highest intensity was selected and presented in the
manuscript (Supporting Information Table S2).
Spearman correlation analysis was used to identify
metabolite-metabolite correlations among all identified metab-
olites and to understand the intra-relation of metabolites.
Spearman correlation coefficients were calculated for all pairs
of annotated features for samples from the discovery and rep-
lication set to account for deviations from linearity. All statis-
tical analyses were performed in R, version 3.3.3.23
Results
Participant characteristics
Characteristics of the study population are summarized in
Table 1. The ColoCare cohort consisted of 63% men in the
colorectal cancer group and 38% men in the control group. In
addition, ColoCare controls had on average less participants
classified as overweight compared to the colorectal cancer
patients. The CORSA cohort consisted of 68% men in the
colorectal cancer group and 65% men in the controls group.
Control patients from the CORSA cohort had on average
slightly more participants categorized as overweight compared
to colorectal cancer patients.
In both cohorts control groups consisted of more partici-
pants categorized as never smokers than compared to the
colorectal cancer patients. In general, the distributions of cov-
ariates were relatively comparable between the discovery and
replication cohorts. Controls from the ColoCare cohort were
13 years younger than controls from the CORSA cohort. The
majority of participants have a BMI classified as overweight,
except for the controls from ColoCare.
Metabolic profiles discriminating between colorectal cancer
patients and controls
Metabolomics analysis yielded 10,015 mass spectrometry fea-
tures, defined as a chromatographic peak formed by specific
ions that were identified across all study samples. After data
pre-processing, 1,156 and 1,148 features were carried forward
for ColoCare and CORSA samples, respectively.
Next, 691 out of 1,156 features were found to be statisti-
cally significantly associated with disease state (discovery
stage) after FDR correction and adjustment for age, sex, BMI,
and smoking status. The 691 significant features were subse-
quently analyzed in the replication dataset, i.e. the CORSA
Study samples. Of these features, 97 differed between CORSA
patients and controls.
The 97 replicated discriminating mass spectrometry fea-
tures corresponded to 28 metabolites, defined as a confirmed
molecule that can consist of one or more features (adducts,
clusters and fragments) (Supporting Information Table S2).
Six metabolites (taurine, hypoxanthine, valine, leucine, biliru-
bin, and 1-methylnicotinamide) were identified using authen-
tic standards resulting in a level 1 identification according to
the Metabolomics Standards Initiative (MSI), nine compounds
(seven lysophosphatidylcholines (LysoPCs) and two lysopho-
sphatidylethanolamines (LysoPEs)) reached MSI level 2 identi-
fication, and 14 compounds could not be identified (unknown
metabolites, MSI level 4). The intensity of these 15 identified
metabolites exhibited significant differences between colorectal
cancer patients and controls in both the discovery and replica-
tion set (Fig. 1). Taurine, hypoxanthine, LysoPE (20:4), and
LysoPE (22:6) showed higher relative mean intensity values in
the colorectal cancer group compared to controls, represent-
ing a OR.std higher than one (Table 2). Valine, leucine, biliru-
bin, 1-methylnicotinamide, and seven LysoPCs (LysoPC(15:0),
LysoPC (16:0), LysoPC(16:0) isomer, LysoPC(P-16:0), LysoPC
(16:1), LysoPC(17:0), LysoPC(18:0)) showed higher relative
mean intensity values in the control group compared to the
colorectal cancer patient group, indicating an OR.std lower
than one (Table 3).
Correlation analysis
Spearman correlation analysis was used to identify potential
metabolite-metabolite correlations among all identified metab-
olites (Fig. 2). Correlation patterns demonstrated similar
results across the discovery (Fig. 2a) and replication stage
(Fig. 2b). For both stages, all LysoPCs were positively
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correlated (Spearman correlation coefficient range [rs]:
0.40–0.91) but showed only a weak correlation to LysoPE
(22:6) and LysoPE (20:4). Valine and leucine were highly cor-
related (discovery stage rs: 0.73, replication stage rs: 0.78). In
addition, the majority of replicated compounds annotated as
unknown (n = 13) were correlated with each other but
showed only weak correlations with the other annotated com-
pounds. Spearman correlation coefficients are shown in Sup-
porting Information Table S3.
Discussion
In our study, we identified plasma metabolites that are associ-
ated with colorectal cancer and which were replicated in an
independent study population. We found 28 metabolites asso-
ciated with disease state in two independent study cohorts,
the ColoCare and CORSA studies. In total, 15 out of 28 metab-
olites could be identified. Taurine, hypoxanthine, valine, leu-
cine, LysoPCs, and LysoPEs have been reported to be linked
with colorectal cancer in previous metabolomics studies. All
LysoPCs were positively correlated, valine and leucine were
highly correlated, and the majority of unidentified metabolites
were correlated with each other. Except for valine and leucine,
the identified metabolites were only slightly or not correlated
with each other.
Taurine was previously shown to be increased in serum of
60 colorectal cancer patients compared to 60 apparently
healthy individuals 13 and in tumor tissue of 16 colorectal
cancer patients; 24 which is in agreement with our findings.
Recent studies have suggested taurine as a microbiota-
associated metabolite playing a mediating role in microbiome-
host interactions.25,26 Given the knowledge that gut microbiota
differ between colorectal cancer patients and healthy individ-
uals, and that microbial composition is linked to colorectal can-
cer risk,27 taurine presents a promising candidate for further
investigation.
Hypoxanthine has been previously reported to be increased
in tumor tissue of colorectal cancer patients compared to nor-
mal tissue of healthy individuals.15 In contrast, a recent study,
Table 1. Demographics and clinical characteristics of colorectal cancer patients and controls1
Discovery stage: ColoCare Study Replication stage: CORSA
CRC patients Controls CRC patients Controls
Number of participants 180 153 88 200
Sex*‡ Men n(%) 114 (63.3) 59 (38.6) 60 (68.2) 130 (65.0)
Age*¥‡ Median (IQR) 66.0 (58.0–73.0) 51.0 (42.0–63.0) 70.0 (60.0–76.0) 64.0 (57.0–74.0)
Body mass index2,*,‡ (kg/m2) Median (IQR) 26.4 (24.1–29.2) 23.5 (22.0–26.7) 26.1 (23.8–29.4) 27.0 (24.9–30.1)
Underweight, <18.5 n(%) 2 (1.1) 19 (12.4) 0 (0) 2 (1.0)
Normal weight, 18.5–24.9 n(%) 59 (32.8) 3 (2.0) 26 (29.5) 47 (23.5)
Overweight, 25–29.9 n(%) 82 (45.6) 91 (59.5) 38 (43.2) 94 (47.0)
Obese, ≥30 n(%) 37 (20.6) 35 (22.9) 15 (17.0) 50 (25.0)
Smoking status* n(%) Current 30 (16.6) 25 (16.3) 20 (22.7) 25 (12.5)
Former 77 (42.8) 47 (30.7) 30 (34.2) 64 (32.0)
Never 61 (33.9) 75 (49.1) 35 (39.7) 104 (52.0)
Unknown 12 (6.7) 6 (3.9) 3 (3.4) 7 (3.5)
Stage3,† n(%) 0 7 (3.9) - 0 (0) -
I 34 (18.9) - 30 (34.1) -
II 66 (36.7) - 17 (19.3) -
III 47 (26.1) - 18 (20.5) -
IV 25 (13.9) - 12 (13.6) -
Unspecified 1 (0.5) - 3 (3.4) -
Unknown 0 (0) - 8 (9.1) -
Tumor location4,† n(%) Colon – distal 53 (29.4) - 21 (31.8) -
Colon – proximal 57 (31.7) - 33 (28.4) -
Rectum 70 (38.9) - 34 (39.8) -
1Controls are defined as individuals not diagnosed with any colorectal malignancy.
2Missing BMI for n = 5, 9 and 7 for ColoCare controls, CORSA CRC patients and controls, respectively.
3TNM for colorectal cancer with neo-adjuvant therapy and colon cancers without surgery (28.7%), else pTNM was used (71.3%).
4Distal colon: sigmoid colon, descending colon, splenic flexure; Proximal colon: transverse colon, hepatic flexure, ascending colon, cecum, appendix;
Rectum: rectum, rectosigmoid junction.
¥p-value <0.05 between ColoCare and CORSA CRC.
†p-value <0.05 between CRC.
‡p-value <0.05 between controls.
*p-value <0.05 between ColoCare and CORSA controls.
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published by Long et al. reported decreased levels of hypoxan-
thine in colorectal cancer and polyps compared to controls.20
Like taurine,5 hypoxanthine is an antioxidant and increased
levels reported in our study may be the result of increased
oxidative stress,28 which is recognized as an important process
in carcinogenesis, including colorectal cancer.29,30 Inconsistent
findings in hypoxanthine levels may be due to the type of
specimen analyzed, or lack of statistical power because of
Figure 1. Box plots of the 15 annotated metabolites differentiating colorectal cancer patients (CRC) and controls for the discovery and
replication set. The box plot presents the minimum, first quartile, median, third quartile and maximum log transformed relative intensity
values and potential outliers of taurine, hypoxanthine, valine, leucine, bilirubin, 1-methylnicotinamide (MNA), LysoPC (15:0), LysoPC (16:0),
LysoPC (16:0) isomer, LysoPC (P-16:0), LysoPC (16:1), LysoPC (17:0), LysoPC (18:0), LysoPE (20:4) and LysoPE (22:6), respectively.
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lower sample numbers included. Furthermore, a possible rea-
son for the inconsistent hypoxanthine levels may be caused by
red blood cell hemolysis during the preparation of serum sam-
ples utilized in the Long study in contrast to plasma used in
the present analysis.31
With respect to branched-chain amino acids (BCAAs), we
observed that valine was reduced among colorectal cancer
patients compared to controls. This result is consistent with
two prior studies; Ma and colleagues compared serum of
30 colorectal cancer patients to 30 colorectal cancer-free
controls,12 and Farshidfar et al. investigated metabolomic sig-
natures in colorectal cancer serum of stage I-IV patients.14
Comparable to valine, decreased plasma levels of leucine were
also reported in our colorectal cancer patients compared to
controls. Decreased blood levels of BCAAs could reflect
increased requirement for amino acids due to the high protein
turnover in the malignant setting.15,19,32
Moreover, seven LysoPCs were detected at lower levels
among colorectal cancer patients compared to controls.
LysoPC (16:0) and LysoPC (18:0) were reported before to be
lower in the plasma of colorectal cancer patients versus con-
trol individuals.33,34 There seems to be a general trend of
lower levels of LysoPCs among colorectal cancer patients in
existing studies,17,33,35 which is in line with the findings
reported in our study. This pattern might reflect an increased
degradation rate of LysoPCs as a result of the accelerated cell
proliferation rate of cancerous cells.36 It has been suggested
that decreased levels of LysoPCs could result from weight loss
and possibly inflammatory processes related to cancer.37,38
While the majority of our study participants were classified as
overweight, we did not have data on changes in body weight
among patients prior to a colorectal cancer diagnosis.
LysoPE (20:4) and LysoPE (22:6) were increased in colo-
rectal cancer patients compared to controls. LysoPEs belong
to the group of signaling lipids and are constituents of cell
membranes. Recently, serum LysoPEs were found to be ele-
vated among breast cancer patients.39 However, knowledge is
limited regarding the role of LysoPEs in healthy and diseased
individuals.
We also identified a notable decrease in MNA, an inactive
metabolite of nicotinamide,40 among colorectal cancer patients
compared to controls. MNA has been reported in vivo to be
involved in the COX-2/PGI2 pathway,
40 which plays a major
role in inflammation and colorectal carcinogenesis.41,42 In
addition, this is the first metabolomics study to report lower
plasma bilirubin levels in colorectal cancer patients compared
to controls. Previously, a European study analyzing genomic
alterations in promoter variants involved in bilirubin homeo-
stasis, and another study investigating serum bilirubin levels
in a large U.S. population have proposed a protective effect of
bilirubin against colorectal carcinogenesis; 43,44 our metabolo-
mics findings carefully support this hypothesis. The underly-
ing mechanisms of the relationship between bilirubin and
colorectal cancer remain unclear.Ta
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Untargeted metabolomics is an elegant approach for the
discovery of metabolites associated with cancer. However, one
may wonder whether the seemingly small differences between
colorectal cancer patients and controls are biologically relevant.
It is important to keep in mind that findings presented are log
transformed relative values. As a consequence, reported results
hint towards the direction of the association and quantification
of the metabolites is needed to be able to interpret absolute dif-
ferences. Our results for taurine, hypoxanthine, valine, leucine,
bilirubin, and 1-methylnicotinamide suggest future research to
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Figure 2. Metabolite-metabolite correlation analysis of replicated metabolites. Positive correlations are highlighted in blue, negative correlations
are highlighted in red. Unknown compounds are indicated as monoisotopic mass@retention time. Metabolites are ordered by hierarchical
clustering. (a) Spearman correlation analysis plot of the discovery dataset. (b) Spearman correlation analysis plot of the replication dataset.
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investigate the underlying biological mechanism of these
metabolites in relation to colorectal cancer.
A strength of the present study is the use of a discovery-
replication design leveraging two independent, relatively large,
patient cohorts, both including patients of Caucasian origin,
from two different countries. In general, untargeted methods
typically yield data with high amounts of noise and nonbiolo-
gical information.45 This makes replication of untargeted
metabolomics findings within ethnically homogenous cohorts
extremely valuable, as it enables the exclusion of features that
are not robustly associated with the case–control status.
A limitation of our study is that due to recruitment proce-
dures we tend to have more early stage colorectal cancer cases
(stage I-II) compared to advanced metastatic patients (stage
IV). This may indicate that our findings are mostly associated
with early metabolic changes in colorectal carcinogenesis
rather than with metastatic formation. Furthermore, findings
are derived from cross-sectional data. Therefore, it is not pos-
sible to explore to which extent metabolites are causally
related to cancer or cancer-related changes. Lastly, although
our study was performed using a single stringent metabolo-
mics approach across two independent populations, we
acknowledge that metabolomics assays can be conducted
using a variety of analytical platforms. As such, future studies
should include multiple platforms to ensure the highest ana-
lytical coverage of the metabolome. Technical progress and
the development of more comprehensive metabolite databases
will also be needed to improve annotation of unknown com-
pounds, including the unknown metabolites in our study.
Future targeted approaches, allowing the quantitative mea-
surement of metabolites, would allow quantification of their
absolute concentrations.46,47
In summary, our study provides new evidence of associa-
tions of colorectal cancer with plasma metabolites and also
confirms some evidence of previous findings.
The combination of an untargeted metabolomics approach,
a rigorous discovery-replication design utilizing large sample
sizes from independent cohorts, led to the identification and
replication of 28 metabolites associated with colorectal cancer,
including 15 metabolites that could be identified. These 15 iden-
tifiable metabolites should be carried forward as candidates for
targeted analysis in prospective cohort studies, preferably
derived from a colorectal cancer screening program, to verify
their discriminating or potential predicting properties. Our
study provides important leads for further studies focusing on
metabolic differences between colorectal cancer-free individuals,
and patients with different stages of colorectal cancer. Together,
our findings emphasize the power of metabolomics as a strong
molecular approach for gaining novel insights regarding meta-
bolic changes associated with colorectal cancer.
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